Biswajit Chowdhury

Biswajit Chowdhury

Auto-generated profile, based on publicly available information

Biswajit Chowdhury

Department of Biochemistry & Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in JACC: Basic To Translational Science
Verified
Journal Article
Open access
ALAlbert Z. Luu
Albert Z. Luu
BCBiswajit Chowdhury
Biswajit Chowdhury
MAMohammed Al-Omran
Mohammed Al-Omran
HTHwee Teoh
Hwee Teoh
DHDavid Hess
David Hess
SVSubodh Verma
Subodh Verma
The clinical use of doxorubicin in cancer is limited by cardiotoxic effects that can lead to heart failure. Whereas earlier work focused on the direct impact of doxorubicin on cardiomyocytes, recent studies have turned to the endothelium, because doxorubicin-damaged endothelial cells can trigger the development and progression of cardiomyopathy by decreasing the release and activity of key endothelial factors and inducing endothelial cell death. Thus, the endothelium represents a novel target for improving the detection, management, and prevention of doxorubicin-induced cardiomyopathy.

1 March 2015 in Molecular Therapy
Verified
Journal Article
Open access
JWJagdeep Walia
Jagdeep Walia
NANaderah Altaleb
Naderah Altaleb
ABAlexander Bello
Alexander Bello
CKChrista Kruck
Christa Kruck
MLMatthew C LaFave
Matthew C LaFave
Barbara Triggs-RaineBarbara Triggs-Raine
Barbara Triggs-Raine
GM2 gangliosidoses are severe neurodegenerative disorders resulting from a deficiency in ß-hexosaminidase A activity and lacking effective therapies. Using a Sandhoff disease (SD) mouse model (Hexb-/-) of the GM2 gangliosidoses, we tested the potential of systemically delivered adeno-associated virus (AAV) 9 expressing Hexb cDNA to correct the neurological phenotype. Neonatal or adult SD and normal mice were intravenously injected with AAV9-HexB or –LacZ and monitored for serum ß-hexosaminidase activity, motor function, and survival. Brain GM2 ganglioside, ß-hexosaminidase activity, and inflammation were assessed at experimental week 43, or an earlier humane end point. SD mice injected with AAV9-LacZ died by 17 weeks of age, whereas all neonatal AAV9-HexB treated SD mice survived until 43 weeks (P<0.0001) with only 3 exhibiting neurological dysfunction. SD mice treated as adults with AAV9-HexB died between 17-35 weeks. Neonatal SD-HexB treated mice had a significant increase in brain ß-hexosaminidase activity, and a reduction in GM2 ganglioside storage and neuroinflammation compared to adult SD-HexB and SD-LacZ treated groups. However, at 43 weeks, 8 of 10 neonatal-HexB injected control and SD mice exhibited liver or lung tumors. This study demonstrates the potential for long-term correction of SD and other GM2 gangliosidoses through early rAAV9 based systemic gene therapy.

1 January 2013 in Journal of Biological Chemistry
Verified
Journal Article
Open access
BCBiswajit Chowdhury
Biswajit Chowdhury
RHRichard Hemming
Richard Hemming
SHSabine Hombach-Klonisch
Sabine Hombach-Klonisch
BFBruno Flamion
Bruno Flamion
Barbara Triggs-RaineBarbara Triggs-Raine
Barbara Triggs-Raine
Hyaluronidase (HYAL) 2 is a membrane-anchored protein that is proposed to hydrolyze hyaluronan (HA) to smaller fragments that are internalized for breakdown. Initial studies of a Hyal2 knock-out (KO) mouse revealed a mild phenotype with high serum HA, supporting a role for HYAL2 in HA breakdown. We now describe a severe cardiac phenotype, deemed acute, in 54% of Hyal2 KO mice on an outbred background; Hyal2 KO mice without the severe cardiac phenotype were designated non-acute. Histological studies of the heart revealed that the valves of all Hyal2 KO mice were expanded and the extracellular matrix was disorganized. HA was detected throughout the expanded valves, and electron microscopy confirmed that the accumulating material, presumed to be HA, was extracellular. Both acute and non-acute Hyal2 KO mice also exhibited increased HA in the interstitial extracellular matrix of atrial cardiomyocytes compared with control mice. Consistent with the changes in heart structure, upper ventricular cardiomyocytes in acute Hyal2 KO mice demonstrated significant hypertrophy compared with non-acute KO and control mice. When the lungs were examined, evidence of severe fibrosis was detected in acute Hyal2 KO mice but not in non-acute Hyal2 KO or control mice. Total serum and heart HA levels, as well as size, were increased in acute and non-acute Hyal2 KO mice compared with control mice. These findings indicate that HYAL2 is essential for the breakdown of extracellular HA. In its absence, extracellular HA accumulates and, in some cases, can lead to cardiopulmonary dysfunction. Alterations in HYAL2 function should be considered as a potential contributor to cardiac pathologies in humans.

1 August 2018 in Atherosclerosis
Verified
Journal Article
Closed access
VLVincent Z. Luu
Vincent Z. Luu
BCBiswajit Chowdhury
Biswajit Chowdhury
MAMohammed Al-Omran
Mohammed Al-Omran
DHDavid A. Hess
David A. Hess
SVSubodh Verma
Subodh Verma

1 January 2017 in Circulation: Cardiovascular Genetics
Verified
Journal Article
Open access
PDF file
BCBiswajit Chowdhury
Biswajit Chowdhury
BXBo Xiang
Bo Xiang
MLMichelle Liu
Michelle Liu
RHRichard Hemming
Richard Hemming
VDVernon W. Dolinsky
Vernon W. Dolinsky
Barbara Triggs-RaineBarbara Triggs-Raine
Barbara Triggs-Raine
Background—: Hyaluronan (HA) is required for endothelial-to-mesenchymal transition and normal heart development in the mouse. Heart abnormalities in hyaluronidase 2 (HYAL2)–deficient ( Hyal2 − /− ) mice and humans suggested removal of HA is also important for normal heart development. We have performed longitudinal studies of heart structure and function in Hyal2 −/− mice to determine when, and how, HYAL2 deficiency leads to these abnormalities. Methods and Results—: Echocardiography revealed atrial enlargement, atrial tissue masses, and valvular thickening at 4 weeks of age, as well as diastolic dysfunction that progressed with age, in Hyal2 −/− mice. These abnormalities were associated with increased HA, vimentin-positive cells, and fibrosis in Hyal2 −/− compared with control mice. Based on the severity of heart dysfunction, acute and chronic groups of Hyal2 −/− mice that died at an average of 12 and 25 weeks respectively, were defined. Increased HA levels and mesenchymal cells, but not vascular endothelial growth factor in Hyal2 −/− embryonic hearts, suggest that HYAL2 is important to inhibit endothelial-to-mesenchymal transition. Consistent with this, in wild-type embryos, HYAL2 and HA were readily detected, and HA levels decreased with age. Conclusions—: These data demonstrate that disruption of normal HA catabolism in Hyal2 −/− mice causes increased HA, which may promote endothelial-to-mesenchymal transition and proliferation of mesenchymal cells. Excess endothelial-to-mesenchymal transition, resulting in increased mesenchymal cells, is the likely cause of morphological heart abnormalities in both humans and mice. In mice, these abnormalities result in progressive and severe diastolic dysfunction, culminating in heart failure.

12 January 2017 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
MMMartina M A Muggenthaler
Martina M A Muggenthaler
BCBiswajit Chowdhury
Biswajit Chowdhury
SHS Naimul Hasan
S Naimul Hasan
HCHarold E Cross
Harold E Cross
BMBrian Mark
Brian Mark
BCBARRY CHIOZA
BARRY CHIOZA
Orofacial clefting is amongst the most common of birth defects, with both genetic and environmental components. Although numerous studies have been undertaken to investigate the complexities of the genetic etiology of this heterogeneous condition, this factor remains incompletely understood. Here, we describe mutations in the HYAL2 gene as a cause of syndromic orofacial clefting. HYAL2, encoding hyaluronidase 2, degrades extracellular hyaluronan, a critical component of the developing heart and palatal shelf matrix. Transfection assays demonstrated that the gene mutations destabilize the molecule, dramatically reducing HYAL2 protein levels. Consistent with the clinical presentation in affected individuals, investigations of Hyal2-/- mice revealed craniofacial abnormalities, including submucosal cleft palate. In addition, cor triatriatum sinister and hearing loss, identified in a proportion of Hyal2-/- mice, were also found as incompletely penetrant features in affected humans. Taken together our findings identify a new genetic cause of orofacial clefting in humans and mice, and define the first molecular cause of human cor triatriatum sinister, illustrating the fundamental importance of HYAL2 and hyaluronan turnover for normal human and mouse development. Cleft lip and palate (CLP) is one of the most common congenital anomalies worldwide. Most of the time the cause is unknown. Affected individuals have multiple problems including difficulties with feeding and speech and have to undergo several operations to correct the orofacial cleft. We describe mutations in an enzyme involved in the development of the palate and heart (Hyaluronidase 2, HYAL2) as the cause of a syndrome of CLP and a congenital heart anomaly (cor triatriatum sinister, CTS) in families from the Amish community and Northern Saudi Arabia of Arabic ethnicity. Mice who lack this enzyme show similar features. HYAL2 is involved in the metabolism of hyaluronic acid, which is important in many tissues of the body. By illustrating a lack of HYAL2 causes CLP and CTS we have demonstrated the importance of HYAL2 for the normal development of the palate and heart, improving our understanding of the complex mechanisms involved in the pathogenesis of CLP and CTS which may ultimately contribute to the development of novel therapies to treat these congenital anomalies.